|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.965 USD | -0.69% |
|
-13.21% | +30.32% |
| 05-09 | Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing | MT |
| 05-09 | Ardelyx Insider Sold Shares Worth $1,831,503, According to a Recent SEC Filing | MT |
Oct 17 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Ardelyx's drug to treat high phosphate levels in patients with chronic kidney disease (CKD), the company said on Tuesday, more than two years after it was initially rejected.
(Reporting by Mariam Sunny, Khushi Mandowara and Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 3,240 JPY | -2.26% | +6.58% | 1.42B | ||
| 7.965 USD | -0.69% | -13.21% | 1.88B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +30.32% | 1.88B | |
| +5.51% | 111B | |
| +11.23% | 105B | |
| -12.17% | 22.34B | |
| -3.00% | 21.93B | |
| -6.13% | 18.59B | |
| -36.52% | 18.12B | |
| -9.51% | 16.96B | |
| +2.84% | 13.7B | |
| +37.66% | 12.45B |
ARDELYX, INC. 
